Drug Trial Radar · NCT05085990
Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b)
Last checked: Nov 19, 2026Latest source record: Jan 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
May 8, 2023
Primary completion
Sep 12, 2024
Study completion Sep 12, 2024
Sponsor
- Lead sponsor
- Protara TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Oct 20, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open-label dose expansion study to investigate the safety and toxicity of intravesical treatment of high-grade NMIBC (HGTa or CIS, including CIS with concomitant Ta) after transurethral resection of bladder tumor (TURBT) and/or biopsy using TARA-002 in adults unable to obtain intravesical Bacillus Calmette-Guérin (BCG), adults who have received at least one dose of intravesical BCG or adults who have received at least one dose of intravesical chemotherapy. After completion of the dose escalation phase (Phase 1a) and after the RP2D has been established, the dose expansion phase (Phase 1b) will start enrollment of subjects with CIS NMIBC with active disease to further evaluate the safety and preliminary efficacy of TARA-002, at the established RP2D. CIS NMIBC with active disease is defined as disease present at the last cystoscopic evaluation prior to signing the ICF. Subjects enrolled in the dose expansion phase will not include subjects previously enrolled and treated in the dose escalation phase. All subjects will receive 6 weeks of treatment at the established RP2D.
Conditions
- Non-muscle Invasive Bladder Cancer
Interventions
TARA-002Biological
Phase 1b, Dose Expansion Phase: All subjects will receive 6 weekly doses of TARA-002 at the recommended Phase 2 dose (R2PD)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1b, Dose Expansion Phase: Incidence of AEs in subjects with CIS NMIBC with active diseaseTime frame: Day 1 to Day 78
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
USC Norris Cancer Center
Los Angeles, California
Mayo Clinic
Jacksonville, Florida
Tulane Medical Center (TMC) - Clinic/Outpatient Facility
New Orleans, Louisiana
Chesapeake Urology Research Associates
Baltimore, Maryland
Mayo Clinic
Rochester, Minnesota
Premier Medical Group of the Hudson Valley
Poughkeepsie, New York
University of Rochester, Department of Urology
Rochester, New York
Carolina Urologic Research Center
Myrtle Beach, South Carolina
Urology Associates PC
Nashville, Tennessee
UT Health San Antonio
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.